All In Biotech

Drug Trial Radar · NCT05083169

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 587 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

587

Actual

Start

Oct 14, 2021

Primary completion

Aug 1, 2025

Study completion Sep 15, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Daratumumab will be administered SC injection.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously.

  • BortezomibDrug

    Bortezomib will be administered SC injection.

  • TeclistamabDrug

    Teclistamab will be administered SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 5 years

Locations

176 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • Stanford University Medical Center

    Stanford, California

  • Yale University

    New Haven, Connecticut

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • Tufts Medical Center

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Henry Ford Health System

    Southfield, Michigan

  • Cleveland Clinic

    Cleveland, Ohio

  • West Penn Hospital

    Pittsburgh, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Baptist Cancer Center

    Memphis, Tennessee

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Aleman

    CABA, Argentina

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, Argentina

  • ZAS Cadix

    Antwerp, Belgium

  • AZ St.-Jan Brugge-Oostende AV

    Bruges, Belgium

  • UZ Gent

    Ghent, Belgium

  • Hopital de Jolimont

    Haine Saint Paul La Louviere, Belgium

  • Az Groeninge

    Kortrijk, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium

  • Hospitais Integradaos da Gavea S/A - DF Star

    Brasília, Brazil

  • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer

    Curitiba, Brazil

  • Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN

    Florianópolis, Brazil

  • Liga Norte Riograndense Contra O Cancer

    Natal, Brazil

  • Irmandade Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

    Rio de Janeiro, Brazil

  • IDOR - Regional Bahia

    Salvador, Brazil

  • Real e Benemerita Associacao Portuguesa de Beneficencia

    São Paulo, Brazil

  • Hospital Paulistano

    São Paulo, Brazil

  • Clinica Medica Sao Germano LTDA

    São Paulo, Brazil

  • Instituto D Or de Pesquisa e Ensino IDOR

    São Paulo, Brazil

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.